Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | prostaglandin D2 receptor (DP) | Starlite/ChEMBL | References |
Homo sapiens | thromboxane A2 receptor | Starlite/ChEMBL | References |
Homo sapiens | prostaglandin D2 receptor 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | rhodopsin orphan GPCR | prostaglandin D2 receptor (DP) | 359 aa | 312 aa | 23.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | putative pyruvate/indole-pyruvate carboxylase, putative | 0.0317 | 0.5333 | 1 |
Mycobacterium tuberculosis | Probable oxalyl-CoA decarboxylase OxcA | 0.0554 | 1 | 1 |
Mycobacterium ulcerans | 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate synthase | 0.0099 | 0.103 | 0.0378 |
Trichomonas vaginalis | pyruvate-flavodoxin oxidoreductase, putative | 0.0081 | 0.0677 | 0.5 |
Treponema pallidum | pyruvate oxidoreductase | 0.0081 | 0.0677 | 0.5 |
Trichomonas vaginalis | pyruvate-flavodoxin oxidoreductase, putative | 0.0081 | 0.0677 | 0.5 |
Echinococcus multilocularis | geminin | 0.0171 | 0.2447 | 1 |
Echinococcus granulosus | geminin | 0.0171 | 0.2447 | 1 |
Mycobacterium tuberculosis | Acetolactate synthase (large subunit) IlvB1 (acetohydroxy-acid synthase) | 0.0237 | 0.3757 | 0.3757 |
Schistosoma mansoni | acetolactate synthase | 0.0474 | 0.8413 | 1 |
Trichomonas vaginalis | pyruvate-flavodoxin oxidoreductase, putative | 0.0081 | 0.0677 | 0.5 |
Loa Loa (eye worm) | ILVBL protein | 0.0336 | 0.5696 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0105 | 0.1165 | 0.1165 |
Mycobacterium ulcerans | acetolactate synthase | 0.0317 | 0.5333 | 0.4994 |
Trypanosoma cruzi | phosphonopyruvate decarboxylase, putative | 0.0179 | 0.2617 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0554 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0117 | 0.1397 | 0.1397 |
Trichomonas vaginalis | pyruvate-flavodoxin oxidoreductase, putative | 0.0081 | 0.0677 | 0.5 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0117 | 0.1397 | 0.1397 |
Mycobacterium leprae | PROBABLE NADH DEHYDROGENASE NDH | 0.0105 | 0.1165 | 0.0151 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0105 | 0.1165 | 0.1165 |
Trichomonas vaginalis | pyruvate-flavodoxin oxidoreductase, putative | 0.0081 | 0.0677 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0171 | 0.2447 | 0.0711 |
Trypanosoma cruzi | phosphonopyruvate decarboxylase, putative | 0.0179 | 0.2617 | 1 |
Leishmania major | phosphonopyruvate decarboxylase-like protein | 0.0179 | 0.2617 | 0.4906 |
Mycobacterium ulcerans | acetolactate synthase large subunit IlvB | 0.0317 | 0.5333 | 0.4994 |
Mycobacterium ulcerans | pyruvate or indole-3-pyruvate decarboxylase Pdc | 0.0317 | 0.5333 | 0.4994 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0105 | 0.1165 | 0.1165 |
Plasmodium falciparum | acyl-CoA synthetase | 0.0317 | 0.5333 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0046 | 0 | 0.5 |
Entamoeba histolytica | pyruvate:ferredoxin oxidoreductase | 0.0081 | 0.0677 | 0.5 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0105 | 0.1165 | 0.1165 |
Plasmodium vivax | acyl-CoA synthetase, putative | 0.0317 | 0.5333 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0179 | 0.2617 | 0.208 |
Schistosoma mansoni | acetolactate synthase | 0.0474 | 0.8413 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0171 | 0.2447 | 0.0711 |
Mycobacterium ulcerans | acetolactate synthase 1 catalytic subunit | 0.0554 | 1 | 1 |
Giardia lamblia | Pyruvate-flavodoxin oxidoreductase | 0.0081 | 0.0677 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase (beta subunit) | 0.0081 | 0.0677 | 0.0677 |
Mycobacterium leprae | PROBABLE ACETOLACTATE SYNTHASE (LARGE SUBUNIT) ILVB (ACETOHYDROXY-ACID SYNTHASE) | 0.0554 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0117 | 0.1397 | 0.1397 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0117 | 0.1397 | 0.0409 |
Trypanosoma brucei | phosphonopyruvate decarboxylase-like protein, putative | 0.0179 | 0.2617 | 1 |
Loa Loa (eye worm) | thiamine pyrophosphate enzyme | 0.0318 | 0.5344 | 0.9382 |
Trypanosoma brucei | phosphonopyruvate decarboxylase-like protein, putative | 0.0179 | 0.2617 | 1 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0105 | 0.1165 | 0.1165 |
Mycobacterium ulcerans | putative oxalyl-CoA decarboxylase | 0.0554 | 1 | 1 |
Mycobacterium leprae | Probable Acetolactate synthase IlvG (Acetohydroxy-acid synthase)(ALS) | 0.0554 | 1 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0105 | 0.1165 | 0.1165 |
Trichomonas vaginalis | pyruvate-flavodoxin oxidoreductase, putative | 0.0081 | 0.0677 | 0.5 |
Mycobacterium tuberculosis | Probable acetolactate synthase IlvG (acetohydroxy-acid synthase)(ALS) | 0.0554 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 3 nM | Antagonist activity at human recombinant CRTH2 receptor expressed in HEK293 cells assessed as inhibition of DK-PGD2-induced intracellular cAMP formation | ChEMBL. | 21106375 |
IC50 (functional) | = 11.5 nM | Antagonist activity at CRTH2 receptor in human whole blood assessed as inhibition of DK-PGD2-induced eosinophils shape change | ChEMBL. | 21106375 |
Ki (binding) | = 4.6 nM | Binding affinity to human recombinant CRTH2 receptor by cell based radioligand equilibrium competition assay | ChEMBL. | 21106375 |
Ki (binding) | = 284 nM | Binding affinity to prostanoid DP1 receptor | ChEMBL. | 21106375 |
Ki (binding) | = 1872 nM | Binding affinity to thromboxane receptor | ChEMBL. | 21106375 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.